Survival in NSCLC cannot be summarized by a single number because outcomes depend on stage (TNM), histologic subtype (adenocarcinoma, squamous, etc.), biomarkers (EGFR, ALK, ROS1, PD-L1), overall health and performance status, and access to appropriate therapy. In early stages (I–II), surgery with indicated adjuvant treatment can lead to long-term disease control and, in some cases, cure. In stages III–IV, the goal is often durable disease control and improved quality of life, though some subsets respond exceptionally well to modern systemic therapy. Targeted therapy and immunotherapy have materially improved survival for selected patients. The most accurate estimate comes from a personalized discussion with your oncology team using your staging and molecular results.